Jaktinib

Overview

Jaktinib is a JAK 1, JAK 2 and JAK 3 inhibitor, being developed by Suzhou Zelgen Biopharmaceuticals. Jaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers	2024/02/07	NCT06246695	Phase 1	Completed	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants	2024/01/05	NCT06193148	Phase 1	Completed	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions	2023/11/15	NCT06132243	Phase 1	Completed	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)	2023/05/16	NCT05861128	Phase 3	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)	2023/05/16	NCT05861102	Phase 3	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)	2023/01/27	NCT05702788	Phase 2	Withdrawn	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia	2023/01/18	NCT05688839	Phase 2	Not yet recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia	2023/01/17	NCT05686629	Phase 2	Not yet recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis	2023/01/09	NCT05676242	Phase 3	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.	2023/01/05	NCT05672888	Phase 2	Not yet recruiting	First Affiliated Hospital of Zhejiang University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access